The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due at least in part to drug resistance of leukemia stem cells (LSCs). Recent clinical evidence suggests that the BCL-2 inhibitor venetoclax in combination with ABL-targeting tyrosine kinase inhibitors (TKIs) can eradicate bpCML LSCs. In this report. we employed preclinical models of bpCML to investigate... https://www.ealisboa.com/great-deal-Pentair-Union-Collar-2-U11-200PS-super-offer/